Homoharringtonine and omacetaxine for myeloid hematological malignancies

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Lü, Shuqing ^a   Wang, Jianmin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; Homoharringtonine; Myelodysplastic syndrome; Omacetaxine

Indexed keywords

ACLARUBICIN; BENZOFURAN DERIVATIVE; CEPHALOTAXINE; CYTARABINE; DAUNORUBICIN; HARRINGTONINE; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; RETINOIC ACID; SILVESTROL; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PROGRESSION FREE SURVIVAL; REVIEW; TACHYCARDIA; TREATMENT DURATION;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 84891953787     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-2     Document Type: Review

References (88)

1. Clinical studies of alkaloids from cephalotaxus fortune Hook. Cooperative Study Group of Zhe Jiang province for Cephalotaxus fortune Hook, Zhe Jiang Zhong Liu Tong Xun 1976 2 14
2. The alkaloids of cephalotaxus drupacea and cephalotaxusfortunei. Paudler WW, Kerley GI, McKay J, J Org Chem 1963 28 2194 2197 10.1021/jo01044a010
3. Structure of cephalotaxine and related alkaloids. Powell RG, Smith CR, Tetrahedron Lett 1969 46 4081 4084
4. Antitumor alkaloids from cephalotaxus harringtonia: structure and activity. Powell RG, Weislede D, Smith CR, J Pharm Sci 1972 61 1227 1230 10.1002/jps.2600610812 5050371
5. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Shanghai Institute of Materia Medica, Shanghai Leukemia Coordinating Group, Provincial People's Hospital of Fukien and Chekiang Cephalotaxus Research Coordinating Group of China, Chin Med J (Engl) 1976 2 263 272 825360
6. The antitumor effects and pharmacologic actions of harringtonine. Institute of Materia Medica, Chinese Med J 1977 3 319 324
7. Homoharringtonine in the treatment of leukemias: clinical analysis of 72 cases. Chinese People's Liberation Army, 187th Hospital, Chinese Med J 1978 3 163 166
8. Phase I clinical investigation of homoharringtonine. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP, Cancer Treat Rep 1984 68 1085 1091 6478448 (Pubitemid 14027401)
9. Phase I trial of homoharringtonine administered as a 5-day continuous infusion. Coonley CJ, Warrell RP Jr, Young CW, Cancer Treat Rep 1983 67 693 696 6871884 (Pubitemid 13001716)
10. A preliminary therapeutic analysis of 82 cases of chronic granulocytic leukemia treated with harringtonine. Zhang ZY, Hou CH, Zhu YF, Chinese J Intern Med 1986 25 156 157 190
11. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M, Blood 1995 86 3322 3326 7579434
12. The treatment of HA regimen in 34 patients with acute non-lymphocytic leukemia. Zheng BG, Luo XS, Zhou YH, Zheng ZY, Shen YP, Lin SY, Hu ZP, Chin J Hematol 1989 10 405 406
13. The treatment of harringtonine in 13 patients with myelodysplastic syndrome. Cao PS, Liu X, Chin J Hematol 1990 11 425
14. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB, Nat Med 1996 2 561 566 10.1038/nm0596-561 8616716 (Pubitemid 26151518)
15. The first semi-synthesis of enantiopure homoharringtonine via anhydro homoharringtonine from a preformed chiral acyl moiety. Robin J, Dhal R, Dujardin G, Girodier L, Mevellec L, Poutot S, Tetrahedron Lett 1999 40 2931 2934 10.1016/S0040-4039(99)00327-5 (Pubitemid 29156607)
16. Inhibition of translation in eukaryotic systems by harringtonine. Fresno M, Jiménez A, Vázquez D, Eur J Biochem 1977 72 323 330 10.1111/j.1432-1033.1977.tb11256.x 319998 (Pubitemid 8022231)
17. Harringtonine, an inhibitor of initiation of protein biosynthesis. Huang MT, Mol Pharmacol 1975 11 511 519 1237080
18. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. Gurel G, Blaha G, Moore PB, Steitz TA, J Mol Biol 2009 389 146 156 10.1016/j.jmb.2009.04.005 19362093
19. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Chen R, Gandhi V, Plunkett W, Cancer Res 2006 66 10959 10966 10.1158/0008-5472.CAN-06-1216 17108134 (Pubitemid 44876995)
20. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myelomapromoting molecules, Mcl-1, XIAP, and beta-catenin. Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Kawata E, Nakagawa Y, Takeuichi M, Murotani Y, Yokota A, Tanaka R, Andreeff M, Taniwaki M, Maekawa T, Int J Hematol 2008 87 507 515 10.1007/s12185-008-0081-8 18415656
21. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z, Legrand O, Marie JP, Mol Cancer Ther 2006 5 723 731 10.1158/1535-7163.MCT-05-0164 16546987
22. Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells. Mai WY, Lin MF, Chin Med J (Engl) 2005 118 487 492 15788130
23. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T, Br J Haematol 2008 140 181 190 18028486 (Pubitemid 350265045)
24. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Lou Y, Jin J, Xu W, Tong X, Am J Hematol 2004 76 199 204 10.1002/ajh.20100 15224352 (Pubitemid 38828836)
25. c-Myc and eIF4F are components of a feed forward loop that links transcription and translation. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J, Cancer Res 2008 68 5326 5334 5322 10.1158/0008-5472.CAN-07-5876 18593934
26. c-Myc and eIF4F constitute a feed forward loop that regulates cell growth: implications for anticancer therapy. Lin CJ, Malina A, Pelletier J, Cancer Res 2009 69 7491 7494 10.1158/0008-5472.CAN-09-0813 19773439
27. Expression and significance of apoptosis protein inhibitor survivin and XIAP, in patients with myelodysplastic syndromes and in the cell line MUTZ-1. Cai Z, Bao HY, Ludwig WD, Wuchter C, Chinese J Hematol 2004 25 26 30
28. Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway. Hu J, He D, Xue X, Gao L, Wu W, Han X, Cai Z, Leuk Lymphoma 2007 48 964 977 10.1080/10428190701216360 17487741 (Pubitemid 47161569)
29. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells. Tong H, Ren Y, Zhang F, Jin J, Eur J Haematol 2008 81 259 266 10.1111/j.1600-0609.2008.01116.x 18616510
30. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR, Blood 2009 113 4656 4666 10.1182/blood-2008-09-175430 19190247
31. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155expressions in acute myeloid leukemia. Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G, J Hematol Oncol 2013 6 21 10.1186/1756-8722-6-21 23497456
32. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on in vitro growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Visani G, Russo D, Ottaviani E, Tosi P, Damiani D, Michelutti A, Manfroi S, Baccarani M, Tura S, Leukemia 1997 11 624 628 10.1038/sj.leu.2400608 9180282 (Pubitemid 27241237)
33. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K, Hughes T, Blood 2003 102 276 283 10.1182/blood-2002-09-2896 12623848 (Pubitemid 36759665)
34. Homoharringtonine induces apoptosis of K562 cells through inhibition of P210bcr/abl. Wang H, Guo Z, Ji S, Zhongguo Shi Yan Xue Ye Xue Za Zhi 2000 8 287 289 12578668
35. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S, Leukemia 2009 23 1446 1454 10.1038/leu.2009.52 19322212
36. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV, Leukemia 2002 16 2349 2357 10.1038/sj.leu. 2402775 12454739 (Pubitemid 36054369)
37. Characterization of cancer stem cells in chronic myeloid leukaemia. Jorgensen HG, Holyoake TL, Biochem Soc Trans 2007 35 Pt 5 1347 1351 17956348 (Pubitemid 350206497)
38. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Allan EK, Holyoake TL, Craig AR, Jørgensen HG, Leukemia 2011 25 985 994 10.1038/leu.2011.55 21468038
39. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T, Cancer Cell 2007 12 528 541 10.1016/j.ccr.2007.11.003 18068630 (Pubitemid 350199070)
40. Beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Hu Y, Chen Y, Douglas L, Li S, Leukemia 2009 23 109 116 10.1038/leu.2008.262 18818703
41. Downregulation of the common cytokine receptor subunit beta c by omacetaxine in CML: a potential molecular mechanism to overcome cytokine-mediated resistance against BCR-ABL-inhibitors. Klag T, Hartel N, Schenk T, Craig AR, Hochhaus A, Rosee PL, Blood 2009 114 3256 Abs
42. Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1. Shen JP, Yang H, Ni WM, Qian WB, Zhejiang Da Xue Xue Bao Yi Xue Ban 2012 41 485 490 23086639
43. A report of 33 cases of chronic granulocytic leukemia treated with harringtonine. Huang ZM, Chen M, Lü LH, Huang SH, Chen ZZ, Liang YY, Fu Jian Yi Ke Da Xue Xue Bao 1998 32 383 384
44. The long-term follow-up results of chronic granulocytic leukemia treated with homoharringtonine. Li YF, Wang CL, Ding BH, Zhu JB, Zheng ST, Yu L, Qian MS, Chin J Hematol 2004 25 378 379
45. The long-term results of 41 cases with chronic granulocytic leukemia treated with homoharringtonine. Li CL, Yu XJ, Bai Xue Bing. Lin Ba Liu 2008 17 142 143
46. Phase I trial of homoharringtonine. Neidhart JA, Young DC, Derocher D, Metz EN, Cancer Treat Rep 1983 67 801 804 6883357 (Pubitemid 13007285)
47. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B, O'Brien S, J Clin Oncol 2000 18 3513 3521 11032593
48. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA, Cancer and Leukemia Group B, Cancer Chemother Pharmacol 2009 63 859 864 10.1007/s00280-008-0805-8 18670778
49. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM, Cancer 2003 98 888 893 10.1002/cncr.11620 12942553 (Pubitemid 37022086)
50. The clinic study of therapy in the chronic myelocytic leukemia-chronic phase by AS2O3 combined with homoharringtonine. He ZG, Hou LJ, Xu JB, J Med Res 2008 37 56 57
51. Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Price KE, Saleem N, Lee G, Steinberg M, Onco Targets Ther 2013 6 1111 1118 23986642
52. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF, Cancer 2005 103 1850 1855 10.1002/cncr.20975 15786422 (Pubitemid 40563257)
53. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J, Cancer 2007 109 248 255 10.1002/cncr.22398 17154172 (Pubitemid 46106239)
54. BCR-ABL (T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Legros L, Hayette S, Nicolini FE, Raynaud S, Chabane K, Magaud JP, Cassuto JP, Michallet M, Leukemia 2007 21 2204 2206 10.1038/sj.leu.2404772 17541396 (Pubitemid 47423816)
55. The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. Nicolini FE, Chomel JC, Roy L, Legros L, Chabane K, Ducastelle S, Nicolas-Virelizier E, Michallet M, Tigaud I, Magaud JP, Turhan A, Guilhot F, Hayette S, Clin Lymphoma Myeloma Leuk 2010 10 394 399 10.3816/CLML.2010.n.073 21030353
56. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H, Omacetaxine 202Study Group, Blood 2012 120 2573 2580 10.1182/blood-2012-03-415307 22896000
57. Clinical observation of low-dose harringtonine combination regimen in the treatment of acute non-lymphocytic leukemia. Wang JM, Zhao ZY, Liu MX, Ju GD, Xu ZH, Zhang P, Chin J Hematol 1989 10 137
58. The effects observation of low-dose Ara-c and harringtonine combination regimen in the treatment of acute leukemia. Huang CL, Qiao QD, Tao L, Chin J Intern Med 1989 28 239
59. Study of the treatment of adult acute non-lymphocytic leukemia. Bian SG, Hao YS, Wang ZC, Chin J Hematol 1993 14 59 62
60. cases of acute myeloid leukemia treated with HA or DA regimen. Fu YH, Liu YZ, Hu Nan Yi Xue 2001 18 390
61. The effects comparison of homoharringtonine and daunorubicin in the treatment of 56 patients with acute myeloid leukemia. Yang M, Chen Q, Chen Y, Pan HP, Acta Acad Med ZUNYI 2005 28 345 346
62. Clinical observation of HAD regien in adult acute myeloid leukemia treatment. Xue YP, Bian SG, Meng QX, Mi YC, Yang DG, Chin J Hematol 1995 16 59 61
63. The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia. Xiao Z, Xue H, Li R, Zhang L, Yu M, Hao Y, Am J Hematol 2008 83 203 205 10.1002/ajh.21068 17874451 (Pubitemid 351307783)
64. The efficacy observation of HAA regimen in acute myeloid leukemia. Wan CC, Guo RC, Zhang ZH, Xia YJ, Lin Chuang Xue Ye Xue Za Zhi 1997 10 92
65. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, Huang J, Mao LP, Tong Y, Wang L, Chen ZM, Xu WL, Leukemia 2006 20 1361 136 10.1038/sj.leu.2404287 16791270 (Pubitemid 44084048)
66. The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia. Song YP, Tong Y, Qian WB, Mai WY, Meng HT, Qian JJ, Tong HY, Huang J, Mao LP, Xu WL, Jin J, Chin J Intern Med 2011 50 48 51
67. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, Hu JD, Wang JM, Li JY, Huang XJ, Ma J, Ji CY, Xu XP, Yu K, Ren HY, Zhou YH, Tong Y, Lou YJ, Ni WM, Tong HY, Wang HF, Mi YC, Du X, Chen BA, Shen Y, Chen Z, Chen SJ, Lancet Oncol 2013 14 599 608 10.1016/S1470-2045(13)70152-9 23664707
68. The treatment of all-transretinoic acid and low-dose homoharringtonine in acute promyelocytic leukemia. Xu JM, Du Y, Zhang LL, Zhong WY, Xue LY, Shan Xi Bai Xue Bing 1992 1 156 158
69. The combination of all-transretinoic acid and low-dose homoharringtonine in the treatment of acute promyelocytic leukemia. Liu QC ZBR, Zhang FX, Guo LH, Ge XR, Chin J Intern Med 2000 39 475 476
70. The clinical analysis of all-transretinoic acid and As2o3 in combination with homoharringtonine for acute promyelocytic leukemia. Lin WQ, Zheng HY, China Prac Med 2009 4 153 154
71. The combination of arsenious acid, retinoic acid, homoharringtonine and cytarabine in the treatment of 20 cases with acute promyelocytic leukemia. Cao LP, Bai Xue Bing. Lin Ba Liu 2006 15 291 292
72. Outcome of acute promyelocytic leukemia with homoharringtonine and ATRA. Yuan Y, Li W, Lin D, Mi YC, Wang Y, Wei H, Liu BC, Zhou CL, Liu KQ, Wang JY, Wei SN, Gong BF, Zhao XL, Sun MY, Wang JX, Chin J Hematol 2011 32 752 757
73. Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia. Pei RZ, Li SY, Zhang PS, Ma JX, Liu XH, Du XH, Chen D, Sha KY, Chen LG, Cao JJ, Zhuang XX, Wu JY, Lin L, Fan Z, Ye PP, Tang SH, Zhang BB, Shi XW, Chin J Hematol 2013 34 144 148
74. Comparison of homoharringtonine and daunorubicin cardiotoxicitv in adults with acute promyelocytic leukemia. Liu KQ, Wei H, Wang HJ, Zhou CL, Liu BC, Lin D, Li W, Wang JY, Wei SN, Gong BF, Zhang GJ, Zhao X, Zhao XL, Mi YC, Wang JX, J Clin Med Pract 2012 16 10 12 17
75. Treatment of HA combination with etoposide or VM-26 in high-risk and refractory adult acute myeloid leukemia. Meng FY, Xu B, Zhou SY, Bai Xue Bing 1999 8 142 143
76. The comparison of efficiencies of CHG and CAG priming regimens in treatment of relapsed or fractory acute myeloid leukemia. Wei XD, Liu YY, Zhang LN, Wang P, Zhang YL, Zhu XH, Song YP, Chin J Hematol 2006 27 64
77. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Zhang WG, Wang FX, Chen YX, Cao XM, He AL, Liu J, Ma XR, Zhao WH, Liu SH, Wang JL, Am J Hematol 2008 83 185 188 10.1002/ajh.20903 17899614 (Pubitemid 351303940)
78. Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism. Ji YY, Zhang WG, Chen YX, Zhao XM, He AL, Liu J, Wang JL, Wang FX, Zhang PY, Zhang WJ, Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010 18 213 218 20137150
79. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. Gu LF, Zhang WG, Wang FX, Cao XM, Chen YX, He AL, Liu J, Ma XR, J Cancer Res Clin Oncol 2011 137 997 1003 10.1007/s00432-010-0947-z 21152934
80. The comparison of efficiencies of HAG and HA regimens in treatment of elderly acute myeloid leukemia. Liu DB, Zhang YJ, Zhu XP, Xu WQ, Sun L, Luo YL, Fu Jian Yi Ke Da Xue Xue Bao 2006 40 274 276
81. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P, Leukemia 1992 6 1189 1191 1434803
82. The treatment of low dose harringtonine in 14 patients with myelodysplastic syndrome. Ji SY, Zhang F, Yang YL, Ding K, Ban Bu Yi Xue Yuan Xue Bao 1997 22 253
83. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA, Leukemia 1996 10 40 42 8558935 (Pubitemid 26052977)
84. Analysis of HAG regimen in the treatment of 28 patients with MDS-RAEB. Shu HE, Li WG, Ge SB, Zhongguo Wu Zhen Xue Za Zhi 2007 7 331 332
85. Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA. Su JY, Chang CK, Zhang X, Zhou LY, Song LQ, Xu L, Wu LY, He Q, Li X, Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009 17 459 463 19379588
86. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q, Leuk Lymphoma 2009 50 1461 1467 10.1080/10428190903096719 19672772
87. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AMLtransformed from MDS. Wu L, Li X, Su J, He Q, Zhang X, Chang C, Pu Q, J Cancer Res Clin Oncol 2011 137 1563 1569 10.1007/s00432-011-1020-2 21845438
88. Design and evaluation of oral delivery dosage forms of homoharringtonine [abstract]. Brown D, Michaels S, Proc 98th Annual Meet Am Assoc Cancer Res 2007 48 4730 abstract